Rexulti
Rexulti (brexpiprazole) is an atypical antipsychotic. It works as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and an antagonist at serotonin 5-HT2A receptors, helping to regulate chemical pathways in the brain to improve mood, thinking, and behavior.
Dosage by Body Weight
Take exactly as prescribed by your doctor, usually once daily with or without food. For Major Depressive Disorder, the starting dose is typically 0.5 mg to 1 mg daily, titrated up to a target dose of 2 mg daily. For Schizophrenia, the starting dose is 1 mg daily, titrated to a target dose of 2 mg to 4 mg daily. For Alzheimer's agitation, the starting dose is 0.5 mg daily, titrated up to 2 mg daily. Dose adjustments are necessary for patients with moderate to severe hepatic or renal impairment, or those who are poor metabolizers of CYP2D6.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Rexulti is not indicated or approved for use in infants or toddlers. Safety and efficacy have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Rexulti is not indicated or approved for use in infants or toddlers. Safety and efficacy have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Rexulti is not indicated or approved for use in pediatric patients of this weight range. Safety and efficacy have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Rexulti is not indicated or approved for use in pediatric patients of this weight range. Safety and efficacy have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Rexulti is not indicated or approved for use in pediatric patients of this weight range. Safety and efficacy have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Rexulti is not indicated or approved for use in infants or toddlers. Safety and efficacy have not been established. |
| 5-7 kg | Not recommended | N/A | Rexulti is not indicated or approved for use in infants or toddlers. Safety and efficacy have not been established. |
| 8-10 kg | Not recommended | N/A | Rexulti is not indicated or approved for use in pediatric patients of this weight range. Safety and efficacy have not been established. |
| 11-15 kg | Not recommended | N/A | Rexulti is not indicated or approved for use in pediatric patients of this weight range. Safety and efficacy have not been established. |
| 16-20 kg | Not recommended | N/A | Rexulti is not indicated or approved for use in pediatric patients of this weight range. Safety and efficacy have not been established. |
Formulation
Purpose
Used as an adjunctive (add-on) treatment for adults with major depressive disorder (MDD), for the treatment of schizophrenia in adults and pediatric patients aged 13 years and older, and for the treatment of agitation associated with dementia due to Alzheimer's disease.
Generic Name
BrexpiprazoleScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.